Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 single-arm multicenter study of crovalimab in pediatric atypical hemolytic uremic syndrome
MOH_2022-01-05_010527Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of crovalimab in atypical hemolytic uremic syndrome (aHUS) (3 cohorts), sponsored by Roche. Started Nov 2021; status: completed.
02
Drugs
crovalimab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on MOH_2022-01-05_010527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-01-05_010527.